SCHEMBL3759813

SCHEMBL3759813

COC(=O)Nc1nc(NC(=O)OC)nc(N(C)C)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.60
GAA P10253 2/20 0.45
CA12 O43570 4/20 0.40
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
CA9 Q16790 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 3/20 0.39
CYP1A2 P05177 2/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
CREBBP Q92793 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.38
MAPT P10636 1/20 0.37
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910688 0.85 LMNA (0.47) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3749011 0.83 POLB (0.42) POLBGAACA12CA1CA2
SCHEMBL2474178 0.76 POLB (0.60) POLBGAACA12CA1CA2
SCHEMBL17451136 0.74 POLB (0.58) POLBGAACA12CA1CA2
SCHEMBL11802485 0.73 POLB (0.68) POLBGAACA12CA1CA2
SCHEMBL3364492 0.72 KMT2A (0.49) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3365341 0.72 HPGD (0.47) GAAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3367290 0.72 KMT2A (0.49) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3366856 0.72 HPGD (0.47) GAAMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL8883302 0.71 MAPT (0.46) POLBGAACA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2160383-B1 N, N',N''-TRIMETHYL-N, N', N''-TRIS(METHOXYCARBONYL)-MELAMINE DERIVATIVES AND SIMILAR TRIAZINE DERIVATIVES FOR AS CROSS-LINKERS AND/OR BINDERS IN COATING COMPOUNDS, PAINTS, INKS, COMPOSITE MATERIALS AND LAMINATES BOREALIS AGROLINZ MELAMINE (AT) 2016-03-09 EP disclosed
US-8569423-B2 Triazine derivatives and a method for their production BOREALIS AGROLINZ MELAMINE GMBH (AT) 2013-10-29 US disclosed
US-8569423-B2 Triazine derivatives and a method for their production BOREALIS AGROLINZ MELAMINE GMBH (AT) 2013-10-29 US disclosed
US-20100292409-A1 Triazine Derivatives and a Method for Their Production BOREALIS AGROLINZ MELAMINE GMBH (AU) 2010-11-18 US disclosed
US-20100292409-A1 Triazine Derivatives and a Method for Their Production BOREALIS AGROLINZ MELAMINE GMBH (AU) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292409-A1 Triazine Derivatives and a Method for Their Production CYP3A5, CYP4Z1, IL5 POLB 3342/4885GAA 844/4885CA12 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.